本公告乃由歐康維視生物（「本公司」，連同其附屬公司，統稱「本集團」）自願作 出，以知會本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事會（「董事會」）欣然宣佈，OT-211 (AR-15512)在中華人民共和國 （「中國」）開展的III期臨床試驗已完成首例患者入組。OT-211 (AR-15512)為一種 0.003%濃度滴眼液配方，亦為首款獲美國食品藥品監督管理局（「FDA」）批准用於 治療乾眼症（「DED」）的TRPM8激動劑。首例患者成功入組標誌著OT-211在中國 的臨床開發取得重要里程碑進展，並體現了本集團致力於為DED患者推進創新療 法。 Alcon Inc.（連同其附屬公司統稱「Alcon集團」）為全球眼科護理領域的領導者，業 務涵蓋手術及視力保健兩大互補板塊，開發出AR-15512的0.003%濃度滴眼液配 方，並完成一項IIb期及三項III期臨床試驗。OT-211 (AR-15512)已於2025年5月 28日獲FDA批准用於治療DED的體徵及症狀。本集團於2024年10月與Alcon集團 進行戰略合作後，已自Alcon集團取得於中國內地開發、製造、委託製造、進口、 出口及銷售O ...

Core Viewpoint - The inclusion of perfluorohexyl octanoate eye drops "Hengqin" in the medical insurance directory has garnered significant attention from individuals suffering from dry eye syndrome, highlighting the growing demand for effective treatments in this area [1][5]. Group 1: Product Information - Perfluorohexyl octanoate eye drops were approved for market release in July 2025 and are designed to stabilize the tear film and prevent excessive evaporation of tear fluid [5]. - The eye drops are priced at 190 yuan for a 3ml bottle, significantly higher than traditional artificial tears, yet they have seen robust sales, exceeding 10,000 units [5]. - The product is specifically indicated for treating dry eye syndrome related to meibomian gland dysfunction (MGD) and is not suitable for all dry eye patients [6]. Group 2: Market Demand and Usage - Over 60% of patients consulting for dry eye symptoms in outpatient settings are seeking treatment, indicating a high prevalence of the condition [5]. - Dry eye syndrome is characterized by insufficient tear production and instability of the tear film, leading to symptoms such as dryness, burning, and discomfort [5][6]. - The treatment landscape for dry eye has traditionally focused on symptom relief, with artificial tears being the most common solution, although they often lack long-lasting effects [6]. Group 3: Treatment Recommendations - Experts recommend a stepwise approach to treating dry eye, emphasizing the need for individualized treatment based on the type and severity of the condition [6]. - Other treatment options include non-steroidal anti-inflammatory drugs, physical therapies, and surgical interventions for severe cases [7]. - Lifestyle modifications, such as using humidifiers and adhering to the "20-20-20" rule for eye care, are also advised to mitigate symptoms [7].

Core Viewpoint - Alcon's FDA approval of Tryptyr 0.003% eye drops for dry eye disease (DED) marks a significant development in the ophthalmic market, while the stock performance of Zhaoke Ophthalmology (06622) reflects broader trends in the pharmaceutical sector, with a notable increase in stock prices across the industry [1][5]. Company Developments - Zhaoke Ophthalmology's stock surged by 19.21% on the same day as Alcon's announcement, continuing a trend where the company's stock has doubled in value over recent months, with a maximum increase of 147.69% since April [1][3]. - The company received FDA approval for a new drug clinical trial application for cyclosporine eye gel, a core product aimed at treating moderate to severe dry eye disease, which is expected to enhance its market position [3][5]. Market Dynamics - The dry eye treatment market in China is projected to grow significantly, with an estimated market size of approximately 160 billion yuan in 2024 and expected to exceed 200 billion yuan by 2025, reflecting a compound annual growth rate (CAGR) of over 15% [5][12]. - Current treatments for dry eye, primarily sodium hyaluronate eye drops, have limitations, leading to a shift towards more effective alternatives like cyclosporine eye gel, which is gaining market share due to its superior efficacy and lower side effects [5][11]. Product Efficacy - Cyclosporine A (CsA) eye gel has shown to significantly improve symptoms in moderate to severe dry eye patients, with a clinical trial indicating a marked improvement in patient outcomes compared to control groups [6][12]. - The formulation of cyclosporine eye gel enhances its bioavailability, achieving peak concentrations in the cornea and conjunctiva that are significantly higher than traditional formulations, thus improving treatment effectiveness [6][7]. Financial Performance - Zhaoke Ophthalmology reported a substantial revenue increase of 268.6% in 2024, with drug sales contributing significantly to this growth, although the company remains in a loss position [12][13]. - The reduction in research and development expenses, alongside increased revenue, has led to a narrowing of losses, indicating a potential turnaround for the company [12][13]. Future Prospects - The anticipated approval and commercialization of cyclosporine eye gel could position Zhaoke Ophthalmology favorably in the market, especially given the high patient compliance rates associated with its formulation [7][11]. - The company is also advancing its pipeline with NVK002, a low-dose atropine product for myopia management, which has received regulatory attention and could further enhance its market presence [13].

UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 * 僅供識別 – 1 – 戰 略 性 擴 充 銷 售 團 隊 ， 整 合 線 上 線 下 渠 道 資 源 ， 覆 蓋 醫 院 、 藥 房 及 主 流 電 商 平 台。從而保證金因康®快速提升市場滲透率和競爭力。 乾眼症患者群體和市場規模持續擴大。相關數據顯示，中國乾眼症市場約有超過 3.6億患者，市場規模預計將以28.4 %的複合年增長率快速擴張，至二零三零年突 破 人 民 幣 420 億 元 。 並 且 ， 隨 著 患 者 對 治 療 便 捷 性 及 安 全 性 需 求 的 提 升 ， 金 因 康®將為應對廣泛存在但尚未被充分滿足的醫療需求，提供強有力的解決方案。 展望未來 ...

2023年10月， 药渡数据库 刊文称，据预计到2030年中国干眼症药物市场规模将大幅增长至 67亿美元 。 干眼症市场具有巨大的潜力和不断增长的患者需求，特别是在中国，随着人口老龄化和现代生活方式的影响，干眼症的患病率和市场规模预计将持续增长。 同时， 患者对于更有效和便捷治疗方式的需求也在不断提升。 干眼常见治疗方式 01 干眼症发病原理 泪膜的结构和功能对于维持眼睛健康至关重要，由 粘 蛋白层、水液层和脂质层构成。 粘蛋白层提供泪膜与眼球表面的粘附力 ，使泪膜能够稳定地附着在眼表，防止泪膜过早破裂。 水液层保持角膜和结膜的湿润 ，提供必要的营养和氧气，帮助清除 眼表的异物和细胞代谢产物。 脂质层减少泪液与空气的接触 ，降低泪液的蒸发速率，维持泪膜的稳定性。 干眼（Dry Eye Disease, DED）是多因素引起的慢性疾病，由泪液的质、量及动力学异常导致的泪膜不稳定或眼表微环境失衡，可伴有眼表炎性反应、组织损伤及 神经异常，造成眼部多种不适症状和/或视功能障碍。 在2007年第1次国际干眼工作小组报告（DEWS 1）中， "干眼症"就已被正式确定为"干眼"，并定义为一种疾病。 根据《国人干眼多中心大 ...